Ribociclib Nitroso Impurity 2

Status: Under Development

It is one of impurity present in Ribociclib, Ribociclib is a selective cyclin-dependent kinase inhibitor by inhibiting two proteins called cyclin-dependent kinase. Inhibition of cyclin-dependent kinase 4 and 6 protect oncogenic processes in specific tissue type. CDK4 is needed for the growth of Ras-induced mammary tumors, suggesting a potential therapeutic window for treatment with lower toxicity. Ribociclib is a selective CDK4/6 inhibitor and has dose-dependent antitumor activity in several preclinical models. It inhibited the growth of tumor cells by arresting the cells at the G1 checkpoint, which prevents the tumor cells from proliferating, also used to treat HR+ and metastatic breast cancer.

Additional information on Ribociclib Nitroso Impurity 2

Catalogue No. VE0010063
Molecular Formula C23H28N10O3
Molecular Weight 492.5 g/mol
Parent drug Ribociclib
IUPAC Name 7-Cyclopentyl-N, N-dimethyl-2-(nitroso(5-(4-nitrosopiperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2, 3-d]pyrimidine-6-carboxamide
Synonyms N/A
References Bartsch, R. (2017). Ribociclib: a valuable addition to treatment options in breast cancer? ESMO Open, 2(3), e000246. https://doi.org/10.1136/esmoopen-2017-000246
Status Under Development

Request a quote

We Respond Within a Few Hours - Whether You're a New or Existing Client

Payment Made Simple: All major Credit/Debit cards accepted

Streamlined 3-Step Process from Quotes to Orders:

Product name:

Ribociclib Nitroso Impurity 2

"*" indicates required fields

Products quotation
This field is for validation purposes and should be left unchanged.